• Home
  • Technology
  • Gaming
  • Entertainment
  • World & Business
  • Science
  • Sports
  • AI
HomeTechnologyGamingEntertainmentWorld & BusinessScienceSportsAI
World & Business

Novo Nordisk reportedly signs Nanexa drug-delivery deal worth up to €1.165 billion

Bloomberg reports that the agreement covers rights to the Swedish company’s drug-delivery technology for obesity and diabetes treatments.

BloombergBL
The Wall Street JournalTW
MarketWatchMA
4 Sources, 16d ago, first seen 16d ago

TLDR

Novo Nordisk signed a deal with Sweden’s Nanexa worth as much as €1.165 billion ($1.3 billion), Bloomberg reports. The agreement is for rights to Nanexa’s drug-delivery technology for obesity and diabetes treatments.

Combined views

160.7K

4 Sources, first seen 16d ago

95 likes24 comments18 saves22 reposts

Combined views

160.7K

4 Sources, first seen 16d ago

95 likes24 comments18 saves22 reposts

Sentiment

Positive——Negative

Summary

Not enough discussion yet.

No sentiment analysis available yet.

Featured Source

Sentiment

Positive——Negative

Summary

Not enough discussion yet.

No sentiment analysis available yet.

Related

Novo Nordisk oral Wegovy and Eli Lilly orforglipron reportedly set for India in first half of 2027

The Economic Times reports Novo Nordisk’s oral Wegovy and Eli Lilly’s orforglipron are expected in India in the first half of 2027, and that top officials said both products have already been submitted to Indian regulators.

4 Sources

Bloomberg@businessNovo Nordisk signed a deal worth as much as €1.165 billion with Sweden’s Nanexa for rights to its drug delivery technology for obesity and diabetes treatments https://www.bloomberg.com/news/articles/2026-09-25/novo-signs-delivery-deal-with-nanexa-worth-up-to-1-3-billion?taid=6ab61f78a627190001d5eef8&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter16d
The Wall Street Journal@WSJNovo Nordisk agreed to license and develop the technology, which could cut the frequency patients need to inject its obesity and diabetes drugs. https://on.wsj.com/3VQl9lJ16d
MarketWatch@MarketWatchAfter capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring https://trib.al/djNjV6A16d
CNBC@CNBCPharma stock soars 150% on injectables deal with Wegovy maker Novo https://www.cnbc.com/2026/09/25/wegovy-novo-nordisk-obesity-drugs.html?taid=6ab6469da627190001d5f001&utm_campaign=trueanthem&utm_content=main&utm_medium=social&utm_source=twitter16d
    • Home
    • Technology
    • Gaming
    • Entertainment
    • World & Business
    • Science
    • Sports
    • AI
    Novo Nordisk

    4 Sources

    Bloomberg@businessNovo Nordisk signed a deal worth as much as €1.165 billion with Sweden’s Nanexa for rights to its drug delivery technology for obesity and diabetes treatments https://www.bloomberg.com/news/articles/2026-09-25/novo-signs-delivery-deal-with-nanexa-worth-up-to-1-3-billion?taid=6ab61f78a627190001d5eef8&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter16d
    The Wall Street Journal@WSJNovo Nordisk agreed to license and develop the technology, which could cut the frequency patients need to inject its obesity and diabetes drugs. https://on.wsj.com/3VQl9lJ16d
    MarketWatch@MarketWatchAfter capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring https://trib.al/djNjV6A16d
    CNBC@CNBCPharma stock soars 150% on injectables deal with Wegovy maker Novo https://www.cnbc.com/2026/09/25/wegovy-novo-nordisk-obesity-drugs.html?taid=6ab6469da627190001d5f001&utm_campaign=trueanthem&utm_content=main&utm_medium=social&utm_source=twitter16d
    Today's Rank

    —

    Not ranked yet

    Today's Rank

    —

    Not ranked yet